Recent literature is equivocal about antipsychotic combination in schizophrenia (1) . However, the advent of the new antipsychotic aripiprazole, which has a mechanism of action different from other atypical antipsychotics, rekindles interest in this field. I describe a patient with schizophrenia showing partial response to olanzapine alone, but showing a marked improvement in symptoms (particularly the negative symptoms) on augmentation with aripiprazole. The possible mechanism of aripiprazole's efficacy in negative symptoms is discussed.
Case Report
Mrs A, a 47-year-old woman with a long-standing history of schizophrenia, was admitted with a psychotic exacerbation precipitated by discontinuation of medicines. On mental status examination, she had marked psychomotor retardation, poverty of speech, flat affect, persecutory and referential delusions, loosening of association, and poor insight and judgment. She scored 122 on the Positive and Negative Symptom Scale (PANSS) with predominant negative symptoms (negative score 46, positive score 25). The patient was restarted on her previous antipsychotic; namely, olanzapine titrated to 20 mg daily, with further increase precluded by increased sedation. Despite 6 weeks on this dosage of olanzapine, there was modest improvement in positive symptoms but none at all in negative symptoms. In view of her partial response to olanzapine, aripiprazole was added at 15 mg daily as an augmenting agent. Within 2 weeks of this addition, the patient began to show improvement in her symptomatology. Her PANSS score dropped to 54 (a drop of 56%) after 6 weeks of olanzapine and aripiprazole combined. The positive, negative, and general psychopathology score decreased by 50%, 69%, and 45%, respectively. The patient was discharged on this combination and continues to maintain her improvement 2 months after discharge, at the same dosage of the 2 drugs. The notable improvement in negative symptoms deserves further attention; possible mechanisms are discussed below.
Olanzapine has a D 2 receptor occupancy of 71% to 80% in the usual clinical dosage range of 10 to 20 mg daily, with the occupancy rising with dosage increase (2) . Aripiprazole also shows a dosedependent D 2 receptor occupancy above 85% at dosages of 10 to 30 mg daily (3). With both olanzapine and aripiprazole having a high D 2 receptor occupancy, one may question the rationale of combining these drugs. However, even at D 2 occupancy values above 90%, extrapyramidal symptoms (EPS) are not observed with aripirazole (3). This may be attributed to aripiprazole's being a partial agonist at the D 2 autoreceptor. It would be interesting to explore how this mechanism may contribute toward improvement in negative symptoms.
Negative symptoms of schizophrenia have been hypothesized to result from a decrease in tonic dopamine transmission (4) . Further, D 2 autoreceptors tonically inhibit dopaminergic neurons (5) . Stimulation of these receptors, as is the case with aripiprazole, induces their desensitization, leading to increased dopamine release (4). This novel mechanism may underlie aripiprazole's low propensity to cause EPS and may also contribute toward its possible efficacy in negative symptoms. The previous generation of atypical antipsychotics, including clozapine, relies mainly on 5-HT 2A antagonism for their greater efficacy in negative symptoms (6) . Though aripiprazole also has a 5-HT 2A antagonistic action, its role as a dopamine autoreceptor agonist may provide additional benefits for countering negative symptoms. Indeed, the study by Kane and colleagues showed that 15 mg daily, but not 30 mg daily, of aripiprazole produced a significantly greater improvement in PANSS negative subscale score, compared with placebo (7). There is some evidence to suggest that dopamine autoreceptor agonists do improve negative symptoms in schizophrenia patients with predominant negative symptoms (8) . As aripiprazole acts as a dopamine agonist in the presence of significant receptor reserve for dopamine (which may be secondary to receptor upregulation following a hypodopaminergic state) (9) , it can be speculated that schizophrenia patients with residual negative symptoms who are on potent D 2 antagonists may benefit from the addition of small doses of aripiprazole. Further studies of aripiprazole at lower and higher dosages in primary negative symptoms are encouraged.
